Biotech stocks jump as Makary outlines FDA vision, RBC comments
Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.
.... .... .... .... .... ....
With biotech stocks still recovering from recent sector-wide weakness, RBC believes the Makary interview could serve as a sentiment boost by reinforcing regulatory stability and predictability. Investors are now seemingly reassessing names positioned in orphan and accelerated approval pathways in light of the evolving FDA leadership tone.
PTX Price at posting:
4.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)